| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone.
|
Hypertension
|
2011
|
3.26
|
|
2
|
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk.
|
Can J Cardiol
|
2005
|
2.13
|
|
3
|
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
|
Can J Cardiol
|
2005
|
2.03
|
|
4
|
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
|
Can J Cardiol
|
2007
|
2.01
|
|
5
|
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
|
Can J Cardiol
|
2012
|
1.86
|
|
6
|
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.
|
Can J Cardiol
|
2013
|
1.85
|
|
7
|
Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization.
|
Circ Res
|
2006
|
1.76
|
|
8
|
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.
|
Can J Cardiol
|
2006
|
1.67
|
|
9
|
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy.
|
Can J Cardiol
|
2002
|
1.49
|
|
10
|
miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications.
|
Diabetes
|
2011
|
1.47
|
|
11
|
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
|
Can J Cardiol
|
2004
|
1.46
|
|
12
|
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
|
Can J Cardiol
|
2010
|
1.44
|
|
13
|
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.
|
Can J Cardiol
|
2009
|
1.42
|
|
14
|
Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2).
|
J Hypertens
|
2013
|
1.42
|
|
15
|
Updated national and international hypertension guidelines: a review of current recommendations.
|
Drugs
|
2014
|
1.41
|
|
16
|
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
|
Can J Cardiol
|
2011
|
1.38
|
|
17
|
The impact of the Canadian Hypertension Education Programme in its first decade.
|
Eur Heart J
|
2009
|
1.26
|
|
18
|
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
|
Can J Cardiol
|
2008
|
1.25
|
|
19
|
The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.
|
Can J Cardiol
|
2004
|
1.20
|
|
20
|
Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization.
|
Nat Cell Biol
|
2002
|
1.19
|
|
21
|
Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation.
|
Am J Physiol Cell Physiol
|
2013
|
1.06
|
|
22
|
Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation.
|
Circulation
|
2003
|
1.03
|
|
23
|
The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification.
|
Can J Cardiol
|
2002
|
1.02
|
|
24
|
Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30.
|
Am J Physiol Cell Physiol
|
2009
|
0.96
|
|
25
|
Choreographing the adenylyl cyclase signalosome: sorting out the partners and the steps.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2011
|
0.95
|
|
26
|
Raf kinase activation of adenylyl cyclases: isoform-selective regulation.
|
Mol Pharmacol
|
2004
|
0.94
|
|
27
|
Barriers to blood pressure control: a STITCH substudy.
|
J Clin Hypertens (Greenwich)
|
2010
|
0.93
|
|
28
|
Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol.
|
Can J Physiol Pharmacol
|
2011
|
0.84
|
|
29
|
Rapid effects of aldosterone on clonal human vascular smooth muscle cells.
|
Am J Physiol Cell Physiol
|
2006
|
0.83
|
|
30
|
Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders.
|
Int J Circumpolar Health
|
2007
|
0.82
|
|
31
|
Identification of a dysfunctional missense single nucleotide variant of human adenylyl cyclase VI.
|
Clin Pharmacol Ther
|
2005
|
0.81
|
|
32
|
Postgame wrap of the ultimate blood pressure megatrial: did it score an ALLHAT trick or was it "three strikes and you're out?".
|
Hypertension
|
2009
|
0.81
|
|
33
|
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
|
Eur J Cardiovasc Prev Rehabil
|
2009
|
0.80
|
|
34
|
Increased enzyme activity and beta-adrenergic mediated vasodilation in subjects expressing a single-nucleotide variant of human adenylyl cyclase 6.
|
Arterioscler Thromb Vasc Biol
|
2007
|
0.80
|
|
35
|
The 2001 Canadian hypertension recommendations: take-home messages.
|
CMAJ
|
2002
|
0.79
|
|
36
|
Increased blood pressure and hyperdynamic cardiovascular responses in carriers of a common hyperfunctional variant of adenylyl cyclase 6.
|
J Pharmacol Exp Ther
|
2010
|
0.79
|
|
37
|
Isoform-specific regulation of adenylyl cyclase function by disruption of membrane trafficking.
|
Mol Pharmacol
|
2004
|
0.79
|
|
38
|
Mineralocorticoids in the heart and vasculature: new insights for old hormones.
|
Annu Rev Pharmacol Toxicol
|
2014
|
0.78
|
|
39
|
The impact of blunted beta-adrenergic responsiveness on growth regulatory pathways in hypertension.
|
Mol Pharmacol
|
2005
|
0.77
|
|
40
|
Regulator of G-protein signaling-2 as a candidate gene: the road to hypertension or just another roadside marker?
|
Hypertension
|
2006
|
0.76
|
|
41
|
New trends in hypertension management: of salt, going solo and single pill combos.
|
Curr Opin Cardiol
|
2010
|
0.76
|
|
42
|
Applying the 2005 Canadian Hypertension Education Program recommendations: 2. Assessing and reducing global atherosclerotic risk among hypertensive patients.
|
CMAJ
|
2005
|
0.76
|
|
43
|
Beyond the shadow: getting past the veil of nonadherence in the management of atherosclerotic risk factors.
|
Can J Cardiol
|
2012
|
0.75
|
|
44
|
Choreographing the rapid vascular effects of estrogen: sorting out the partners and the steps.
|
Hypertension
|
2007
|
0.75
|
|
45
|
Managing hypertension: evidence supporting the 2013/2014 recommendations of the Canadian Hypertension Education Program.
|
CMAJ
|
2014
|
0.75
|
|
46
|
New tools, old challenges: the emerging role of angiotensin receptor blockers in the treatment of the systolic hypertension epidemic.
|
Can J Cardiol
|
2004
|
0.75
|
|
47
|
High blood pressure selected as the theme for World Health Day, April 7, 2013: cup half full or half empty?
|
Can J Cardiol
|
2013
|
0.75
|
|
48
|
Sixty years of Pharmacological Reviews: has the role of review articles in biomedical sciences changed and, if so, how does this affect Pharmacological Reviews?
|
Pharmacol Rev
|
2009
|
0.75
|